RARE Ultragenyx Pharmaceutical Inc.
$16.75▲ +4.17%
Healthcare
Other
After hours
$16.93▲ +1.10%
Oct 27, 5:42 PM ET
Volume 4.94M
Avg Volume (10D) 3.11M
Key Metrics & Fundamentals
Market Cap
$1.65B
P/E Ratio
–
Div Yield
0.00%
52W Range
12.73 - 39.89
% vs 50 MA
-4.57%
% vs 200 MA
-27.20%
RSI-14
56.4
MACD Histogram
+0.3800
Beta (1Y vs SPY)
1.26
Free Cash Flow
-$98.00M
Gross Rev
$214.00M
Gross Profit
$180.00M
EBITDA
-$61.00M
COGS
$34.00M
Operating Exp
$255.00M
Operating Income
-$75.00M
EBIT
-$75.00M
Pretax Income
-$91.00M
Net Income
-$92.00M
EPS (Diluted)
-0.90
Price & Volume History
Loading chart…
Recent News
Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update
GlobeNewswire · Oct 27, 2026 4:05 PM ET
Broadcom upgraded, HubSpot downgraded: Wall Street's top analyst calls
The Fly · Oct 27, 2026 9:40 AM ET
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Zacks · Oct 27, 2026 9:00 AM ET
Sector Update: Healthcare Stocks Softer Monday Afternoon
MT Newswires · Oct 19, 2026 1:52 PM ET
Ultragenyx Pharmaceutical Enters Settlement With Navinta Over Dojolvi
MT Newswires · Oct 19, 2026 10:51 AM ET
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week
Zacks · Oct 15, 2026 9:33 AM ET
Sector Update: Healthcare
MT Newswires · Oct 14, 2026 3:34 PM ET
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?
Zacks · Oct 14, 2026 9:30 AM ET
Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher for $203 Million
MT Newswires · Oct 14, 2026 9:08 AM ET
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million
GlobeNewswire · Oct 14, 2026 8:30 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See RARE's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.